유럽 ​​뇌졸중 진단 시장 규모, 점유율 및 동향 분석 보고서 – 산업 개요 및 2033년까지의 전망

유럽 ​​뇌졸중 진단 시장 규모

• 유럽 ​​뇌졸중 진단 시장 규모는 2025년 11억 5천만 달러 였으며, 예측 기간 동안 연평균 6.0%의 성장률을 기록하여 2033년에는 18억 3천만 달러  에 이를 것으로 예상됩니다  .
• 시장 성장은 유럽 인구 전반에 걸쳐 뇌졸중 발생률과 유병률이 증가하고, 고령화가 진행되며, 뇌혈관 질환을 조기에 정확하게 진단할 수 있는 첨단 진단 영상 기술이 빠르게 도입되고 있는 데 힘입어 크게 촉진되고 있습니다.
• 더 나아가, 증가하는 의료 투자, 조기 뇌졸중 치료를 위한 정부 지원 정책, 그리고 병원 및 영상 센터에서 시의적절하고 정확하며 통합적인 진단 솔루션에 대한 수요 증가로 인해 뇌졸중 진단은 현대 뇌졸중 치료 경로의 핵심 요소로 자리매김하고 있습니다. 이러한 여러 요인들이 복합적으로 작용하여 혁신적인 진단 도구의 도입을 가속화하고 있으며, 이는 관련 산업의 성장을 크게 촉진하고 있습니다.

유럽 ​​뇌졸중 진단 시장 분석

• 첨단 영상 기술과 바이오마커 기반 도구를 포함하는 뇌졸중 진단은 뇌혈관 질환을 조기에 발견하고 사망률을 줄이며 환자 예후를 개선하는 데 중요한 역할을 하므로 현대 의료에서 ​​점점 더 중요해지고 있습니다. 이는 유럽 전역의 병원 및 진단 센터에서 널리 시행되고 있습니다.
• 뇌졸중 진단 수요 증가의 주요 원인은 고령 인구의 뇌졸중 발병률 증가, 조기 진단의 중요성에 대한 인식 제고, 그리고 CT, MRI, AI 기반 진단 시스템과 같은 영상 진단 기술의 발전입니다.
• 독일은 잘 구축된 의료 인프라, 조기 뇌졸중 진단을 지원하는 정부 정책, 그리고 첨단 영상 기술의 높은 도입률에 힘입어 2025년까지 뇌졸중 진단 시장에서 28.5%의 최대 매출 점유율을 기록하며 선두를 차지할 것으로 예상됩니다.
• 폴란드는 의료 인프라 개선, 의료비 지출 증가, 최첨단 진단 도구 접근성 향상으로 인해 예측 기간 동안 뇌졸중 진단 시장에서 가장 빠르게 성장하는 국가가 될 것으로 예상됩니다.
• 컴퓨터 단층촬영(CT 스캔) 부문은 빠른 영상 촬영 기능, 급성 뇌졸중 진단에서의 높은 정확도, 그리고 병원 뇌졸중 치료 프로토콜에 널리 통합되어 있다는 장점에 힘입어 2025년까지 뇌졸중 진단 시장에서 60.4%의 점유율을 차지하며 주도적인 역할을 할 것으로 예상됩니다.

보고서 범위 및 유럽 뇌졸중 진단 시장 세분화   

유럽 ​​뇌졸중 진단 시장 동향

인공지능 기반 영상 촬영 및 신속 진단 분야의 발전

• 유럽 ​​뇌졸중 진단 시장에서 중요하고 빠르게 가속화되는 추세는 인공지능(AI) 및 머신러닝 알고리즘을 CT 및 MRI와 같은 영상 기술과 통합하여 급성 뇌졸중 환자의 진단 속도와 정확도를 향상시키는 것입니다.
• 예를 들어, AI 기반 CT 시스템은 허혈 부위를 자동으로 감지하여 방사선 전문의가 위급 사례의 우선순위를 정하고 응급 상황에서 치료까지 걸리는 시간을 단축할 수 있도록 합니다.
• 인공지능 기반 영상 도구는 수동 판독 과정에서 놓칠 수 있는 미묘한 이상 징후를 식별할 수 있으며, 예측 알고리즘은 위험 평가를 제공하고 환자에게 맞춤형 치료 계획을 제안합니다.
• 인공지능 진단과 병원 정보 시스템의 완벽한 결합은 환자 영상 데이터의 중앙 집중식 관리를 가능하게 하여 뇌졸중 치료팀 전체의 효율적인 의사 결정 및 치료 계획 수립을 지원합니다.
• 원격진료 플랫폼과 뇌졸중 진단의 통합은 특히 의료 서비스가 부족한 지역에서 원격 판독 및 전문가 상담을 가능하게 하여 시기적절한 치료를 가속화하고 있습니다.
• 보다 빠르고 정확하며 데이터 기반의 뇌졸중 진단을 향한 이러한 추세는 임상 워크플로우를 재편하고 있으며, 브레인오믹스(Brainomix)와 같은 기업들은 표준 CT 영상 플랫폼과 통합된 AI 기반 뇌졸중 평가 도구를 개발하고 있습니다.
• 유럽 ​​전역의 병원과 진단 센터에서 인공지능(AI) 기반 뇌졸중 진단에 대한 수요가 급증하고 있는데, 이는 의료진이 치료 지연을 줄이고 환자 예후를 개선하고자 하기 때문입니다.

유럽 ​​뇌졸중 진단 시장 동향

운전사

뇌졸중 발병률 증가 및 조기 발견의 필요성 증대

• 고령화 사회에서 뇌졸중 발병률이 증가하고 시의적절한 치료의 필요성이 높아짐에 따라 유럽에서 첨단 뇌졸중 진단 도구에 대한 수요가 증가하고 있습니다.
• 예를 들어, 지멘스 헬스케어는 2025년 3월에 병원에서 뇌졸중을 더 빨리 발견할 수 있도록 AI 기반 CT 솔루션을 출시하여 조기 진단 및 환자 분류를 개선하는 것을 목표로 했습니다.
• 신속한 뇌졸중 진단의 중요성에 대한 인식이 높아짐에 따라, 의료 서비스 제공자들은 정확한 진단, 향상된 업무 효율성 및 통합적인 환자 관리를 제공하는 영상 기술을 점점 더 많이 도입하고 있습니다.
• 더 나아가, 조기 뇌졸중 치료를 지원하는 정부 정책과 의료 투자 덕분에 병원들은 첨단 CT, MRI 및 AI 지원 도구를 활용하여 진단 인프라를 업그레이드하고 있습니다.
• 인공지능 기반 뇌졸중 진단에 대한 의료 전문가 대상 교육 프로그램 및 인식 개선 캠페인이 확대되면서 병원 및 진단 센터 전반에 걸쳐 인공지능 활용이 더욱 촉진되고 있습니다.
• 확장 가능한 뇌졸중 진단 솔루션을 구현하기 위한 영상 기술 제공업체와 의료 시스템 간의 협력은 시장 침투율을 높이고 임상 워크플로 효율성을 개선하는 데 기여하고 있습니다.
• 뇌졸중 유형과 심각도를 신속하게 식별하는 능력과 병원 정보 시스템 및 전자 건강 기록과의 통합이 결합되어 공공 및 민간 의료 시설 전반에 걸쳐 도입이 가속화되고 있습니다.

절제/도전

"높은 장비 비용 및 규정 준수 장벽"

• The high capital investment required for advanced imaging systems and AI-assisted diagnostic tools poses a significant challenge to market growth, particularly for smaller hospitals and clinics
• For instance, advanced CT scanners with AI capabilities can cost several hundred thousand euros, limiting adoption in budget-constrained healthcare facilities
• Additionally, navigating complex European medical device regulations, including CE marking and data privacy compliance for AI tools, can slow deployment and raise operational costs
• While initiatives are underway to streamline approvals and provide financial incentives, regulatory and budgetary hurdles continue to limit market penetration in some countries
• Lack of standardized protocols for AI-assisted diagnostics can result in variability of results and reduce clinician confidence, presenting an adoption barrier
• Maintenance costs and the need for regular software updates for AI-integrated systems add ongoing operational expenses, which can hinder adoption in cost-sensitive healthcare settings
• Addressing these challenges through cost-effective imaging solutions, scalable AI software, and regulatory support will be critical to sustaining growth in the European stroke diagnostics market

Europe Stroke Diagnostics Market Scope

The market is segmented on the basis of severity, type, application, end user, distribution channel, and stage.

• By Severity

On the basis of severity, the market is segmented into mild, moderate, and severe strokes. The severe stroke segment dominated the market with the largest revenue share of 48.6% in 2025, driven by the high demand for rapid, advanced diagnostic interventions to minimize mortality and long-term disability. Hospitals prioritize advanced imaging and AI-assisted diagnostics for severe cases due to their urgency and the need for immediate treatment decisions. The rising prevalence of severe strokes in aging populations across Europe, particularly in countries such as Germany and France, contributes to the segment’s dominance. Additionally, government initiatives and hospital protocols mandate comprehensive imaging for severe stroke cases, further propelling demand. Continuous technological advancements in CT, CTA, and MRI specifically for acute and severe stroke assessment also strengthen this segment’s market position. Clinicians rely on accurate severity assessment to optimize treatment pathways and patient monitoring, making this subsegment critical for market growth.

The mild stroke segment is expected to witness the fastest growth at a CAGR of 7.8% from 2026 to 2033, fueled by rising awareness and early detection programs. AI-assisted imaging and portable diagnostic tools are increasingly used to identify mild strokes that may have subtle presentations. Countries with well-developed primary healthcare systems, such as the U.K. and Sweden, are investing in routine screenings and mobile diagnostic units. Telemedicine and wearable monitoring devices further accelerate detection and reporting of mild stroke events. The adoption of early diagnostic technologies reduces long-term complications and healthcare costs, making mild stroke diagnostics a rapidly expanding segment. Preventive care programs promoting regular check-ups and early intervention are key drivers for growth in this segment.

• By Type

On the basis of type, the market is segmented into Computed Tomography (CT Scan), Computed Tomography Angiography (CTA), Magnetic Resonance Imaging (MRI), Magnetic Resonance Angiography (MRA), Transcranial Doppler Ultrasound, Video Head Impulse Test (VHIT), and others. The Computed Tomography (CT Scan) segment dominated the market with a revenue share of 60.4% in 2025, driven by its rapid imaging capability, high diagnostic accuracy, and widespread hospital adoption. CT scans are the first-line diagnostic tool for suspected stroke patients due to their speed and reliability in detecting ischemic and hemorrhagic events. The integration of AI with CT technology allows automated lesion detection and triage, reducing time-to-treatment. Hospitals in Germany, France, and Italy rely heavily on CT imaging for acute stroke management, contributing to its dominant share. Emergency departments prioritize CT scans because of their ability to quickly identify stroke type, guide thrombolytic therapy, and monitor treatment efficacy. Increasing availability of multi-slice CT scanners and continuous software upgrades further strengthen the segment’s market position.

The CTA segment is expected to witness the fastest growth at a CAGR of 8.5% from 2026 to 2033, driven by its ability to provide detailed vascular imaging for precise diagnosis and treatment planning. CTA enables visualization of cerebral arteries, helping clinicians identify occlusions and aneurysms accurately. AI integration in CTA systems allows automated vessel analysis and risk scoring, enhancing clinical decision-making. The growing prevalence of complex stroke cases and expanding hospital imaging infrastructure across Eastern Europe fuels CTA adoption. Additionally, collaborations between imaging solution providers and healthcare centers are facilitating more accessible CTA diagnostics. The segment’s growth is also supported by increasing demand for minimally invasive interventions guided by high-resolution vascular imaging.

• By Application

On the basis of application, the market is segmented into ischemic stroke, hemorrhagic stroke, and transient ischemic attacks (TIAs). The ischemic stroke segment dominated the market with a share of 55.4% in 2025, driven by its higher prevalence and the critical need for early and accurate diagnosis. Hospitals rely on advanced imaging modalities, such as CT and MRI, combined with AI-assisted analysis, to determine the location and extent of ischemic injury. Clinical guidelines emphasize rapid imaging and treatment to prevent long-term neurological deficits, supporting high demand for ischemic stroke diagnostics. Investments in stroke units and government-led awareness programs in Germany, France, and the U.K. accelerate the segment’s growth. AI-based predictive tools further aid in patient triage and risk assessment. The prevalence of lifestyle-related risk factors, such as hypertension and diabetes, also increases the need for timely ischemic stroke detection.

The TIA segment is expected to witness the fastest growth at a CAGR of 7.2% from 2026 to 2033, fueled by increasing awareness and preventive care initiatives. Early detection of TIAs can significantly reduce the risk of subsequent major strokes. Telemedicine and wearable monitoring systems help capture transient events, supporting growth in outpatient and home-based care. Countries like Sweden and the Netherlands are implementing TIA screening programs and mobile imaging units, further driving adoption. AI-assisted tools help clinicians predict potential recurrent events and optimize patient management. The rising focus on reducing healthcare burden through preventive diagnostics is a key factor supporting growth in this subsegment.

• By End User

On the basis of end user, the market is segmented into hospitals, clinics, ambulatory surgical centers, and home healthcare. The hospitals segment dominated the market with a share of 68.7% in 2025, due to the high adoption of advanced imaging technologies, AI-assisted diagnostics, and availability of specialized stroke units. Hospitals in Germany, France, and the U.K. offer integrated diagnostic and treatment pathways for stroke patients, driving demand for comprehensive stroke diagnostics. High patient volumes, regulatory mandates for rapid intervention, and well-equipped emergency departments strengthen the segment’s market position. AI-powered CT and MRI solutions are being implemented to enhance workflow efficiency and reduce treatment delays. Hospitals also invest in continuous staff training and software upgrades to maintain diagnostic accuracy. Collaborations with imaging technology providers further support hospital adoption of advanced stroke diagnostics.

The home healthcare segment is expected to witness the fastest growth at a CAGR of 8.0% from 2026 to 2033, fueled by rising demand for remote monitoring of high-risk patients. Portable imaging devices, telemedicine solutions, and wearable sensors allow early detection of stroke symptoms in home settings. Aging populations in countries like Italy, Spain, and Poland increase demand for home-based care. AI-driven predictive tools alert caregivers to potential events, supporting timely intervention. Government and insurance initiatives promoting remote care solutions further contribute to this segment’s rapid growth. Home healthcare integration improves patient convenience while reducing hospital readmissions and long-term costs.

• By Distribution Channel

On the basis of distribution channel, the market is segmented into direct tender, third-party distributors, and others. The direct tender segment dominated the market with a share of 54.3% in 2025, driven by hospital procurement policies that prioritize direct acquisition from manufacturers for better pricing, after-sales support, and guaranteed compliance with European medical standards. Large hospitals in Germany, France, and the U.K. prefer direct tenders for acquiring advanced CT, CTA, and MRI systems. Direct procurement ensures customization, timely delivery, and service agreements, enhancing operational efficiency. Manufacturers often provide on-site installation, training, and maintenance services through direct tenders. Long-term contracts and bulk orders for advanced diagnostic systems further strengthen this segment. Hospitals also rely on direct tenders to implement AI-integrated solutions tailored to clinical workflow requirements.

The third-party distributors segment is expected to witness the fastest growth at a CAGR of 7.5% from 2026 to 2033, fueled by the increasing presence of medical device distributors in emerging European markets. Smaller clinics and diagnostic centers rely on distributors for flexible purchasing and access to multiple brands. Distributors also provide installation, maintenance, and staff training services, making advanced diagnostics more accessible. Expanding distribution networks in countries such as Poland, Hungary, and Romania accelerate adoption of advanced stroke diagnostic tools. The flexibility and cost-effectiveness of third-party channels support rapid market penetration. Partnerships between distributors and manufacturers further enhance service and availability in remote locations.

• By Stage

On the basis of stage, the market is segmented into pre-operative, peri-operative, and post-operative. The pre-operative segment dominated the market with a share of 62.1% in 2025, as early diagnosis and assessment are critical for planning interventions such as thrombolysis or thrombectomy. Hospitals rely on advanced CT, CTA, and MRI imaging, combined with AI-assisted predictive analytics, to determine treatment strategy. Clinical guidelines mandate rapid pre-operative imaging to optimize outcomes in acute stroke cases. Countries like Germany, France, and the U.K. emphasize pre-operative imaging protocols in stroke care pathways. High adoption of AI-based tools for severity assessment further strengthens this segment. Pre-operative imaging also reduces treatment errors and improves patient triage efficiency.

The post-operative segment is expected to witness the fastest growth at a CAGR of 7.4% from 2026 to 2033, driven by increasing demand for follow-up imaging and monitoring of stroke patients. Post-operative diagnostics help detect complications, assess recovery, and guide rehabilitation. Integration of AI-assisted imaging allows continuous monitoring of cerebral changes and vascular status. Home-based imaging and telemedicine platforms support follow-up for patients in remote areas. Governments and insurance providers encourage post-operative monitoring to reduce readmissions. The focus on patient safety, recovery optimization, and long-term outcomes propels growth in post-operative stroke diagnostics.

Europe Stroke Diagnostics Market Regional Analysis

• Germany dominated the stroke diagnostics market with the largest revenue share of 28.5% in 2025, driven by well-established healthcare infrastructure, government initiatives supporting early stroke detection, and high adoption of advanced imaging technologies
• Hospitals and diagnostic centers in Germany prioritize rapid, accurate stroke detection, leveraging CT, CTA, and MRI systems integrated with AI to reduce time-to-treatment and improve patient outcomes
• This strong adoption is further supported by government initiatives promoting early stroke intervention, high healthcare expenditure, and well-established clinical guidelines, positioning Germany as a key market for advanced stroke diagnostics in Europe

The Germany Stroke Diagnostics Market Insight

The Germany stroke diagnostics market is expected to expand at a considerable CAGR during the forecast period, fueled by increasing awareness of early stroke detection and the demand for technologically advanced diagnostic solutions. Hospitals extensively deploy AI-assisted CT, CTA, and MRI systems for rapid, accurate diagnosis and treatment planning. Government support for stroke care programs, investment in stroke units, and integration of diagnostics into standard hospital protocols strengthen adoption. The focus on preventive care and telemedicine-supported imaging solutions further drives growth. Hospitals in major cities, including Berlin, Munich, and Frankfurt, are implementing advanced stroke diagnostics to reduce mortality and improve patient outcomes. Germany’s emphasis on innovation, high healthcare expenditure, and collaboration with diagnostic technology providers positions it as the leading country in Europe for stroke diagnostics.

U.K. Stroke Diagnostics Market Insight

The U.K. stroke diagnostics market is projected to grow at a substantial CAGR throughout the forecast period, fueled by rising stroke awareness and increasing investment in advanced imaging technologies. The widespread deployment of AI-enabled CT and MRI systems in hospitals allows for faster triage and improved patient outcomes. Public health programs emphasize rapid diagnosis and early intervention, encouraging adoption across both urban and semi-urban healthcare centers. Growing demand for integrated hospital workflows and telemedicine-supported diagnostics further strengthens market expansion. The U.K.’s robust healthcare infrastructure and trained workforce enhance the effective utilization of stroke diagnostics. Rising prevalence of lifestyle-related risk factors, such as hypertension and diabetes, also drives demand for timely stroke detection.

France Stroke Diagnostics Market Insight

The France stroke diagnostics market is expected to expand at a notable CAGR during the forecast period, primarily driven by increasing incidence of stroke and government-led preventive care initiatives. Hospitals are rapidly adopting AI-assisted imaging platforms to improve the accuracy and speed of stroke diagnosis. Public awareness campaigns on early stroke detection and rehabilitation further boost the demand for advanced diagnostic tools. The country is witnessing growth across both public and private healthcare facilities, with imaging solutions incorporated into standard hospital protocols. Expansion of stroke units in urban centers and improved access to CT and MRI systems are accelerating market penetration. Moreover, collaborations between technology providers and hospitals enhance availability of innovative diagnostic solutions.

Poland Stroke Diagnostics Market Insight

The Poland stroke diagnostics market is expected to witness the fastest CAGR during the forecast period, due to improving healthcare infrastructure, increasing access to modern imaging technologies, and rising government support for stroke prevention programs. Hospitals and clinics are upgrading to AI-integrated CT and CTA systems, improving early detection and patient triage. Public awareness campaigns and training for medical professionals on advanced stroke diagnostics accelerate adoption. Expansion of stroke care centers in smaller cities and rural areas further contributes to growth. The market is also supported by collaborations with international diagnostic solution providers. Increased healthcare spending and policy incentives for early intervention drive the rapid adoption of stroke diagnostics across Poland.

Europe Stroke Diagnostics Market Share

The Europe Stroke Diagnostics industry is primarily led by well-established companies, including:

• Siemens Healthineers AG (Germany)
• Koninklijke Philips N.V. (Netherlands)
• GE HealthCare (U.S.)
• CANON MEDICAL SYSTEMS CORPORATION (Japan)
• Shenzhen Mindray Bio Medical Electronics Co., Ltd. (China)
• FUJIFILM Holdings Corporation (Japan)
• Analogic Corporation (U.S.)
• Aspect Imaging Ltd (Israel)
• Carestream Health (U.S.)
• Esaote S.p.A (Italy)
• Hologic, Inc. (U.S.)
• IMRIS Inc. (Canada)
• Fonar Corporation (U.S.)
• Medfield Diagnostics AB (Sweden)
• MEDTRON AG (Germany)
• SAMSUNG Medison (South Korea)
• Shenzhen Anke High Tech Co., Ltd. (China)
• Shimadzu Corporation (Japan)
• ALPINION MEDICAL SYSTEMS Co., Ltd. (South Korea)
• BPL Medical Technologies (India)

What are the Recent Developments in Europe Stroke Diagnostics Market?

• In September 2025, Brainomix’s Brainomix 360 Stroke AI imaging platform garnered attention after real‑world data demonstrated that its use significantly improved functional recovery rates and increased mechanical thrombectomy use, highlighting the growing impact of AI‑enabled diagnostics in stroke care
• In June 2025, Royal Philips announced the CE‑mark approval and Europe launch of its latest SmartCT image reconstruction solution, enabling intelligent 3D imaging in the angio suite to support faster stroke decision‑making and reduce delays during time‑critical procedures such as mechanical thrombectomy
• In March 2025, Europe‑wide discussions and pilot initiatives around faster prehospital diagnosis with innovations like mobile stroke units and rapid diagnostic techniques highlighted ongoing efforts to reduce time‑to‑diagnosis outside traditional hospital settings, indicating broader innovation momentum in stroke diagnostics
• 2024년 11월, Hyperfine, Inc.는 최신 AI 기반 휴대용 MRI 뇌 영상 소프트웨어인 Swoop®의 CE 승인 및 유럽 출시를 발표했습니다. 이 소프트웨어는 다양한 의료 환경에서 더 빠르고 고품질의 MR 영상을 구현하여 뇌졸중과 같이 시간에 민감한 질환에 대한 중요한 진단 결정을 지원합니다. 또한 응급실에서 신속한 MRI 검사에 대한 접근성을 개선하고 유럽 전역에 첨단 뇌 영상 기능을 확대합니다.
• 2024년 10월, 지멘스 헬스케어는 EU 자금 지원으로 진행되는 UMBRELLA 프로젝트 출범을 공동 주도했습니다. 이 프로젝트는 2,690만 유로 규모의 범유럽 사업으로, 디지털화, AI 기반 알고리즘, 실제 데이터를 활용하여 유럽 여러 국가의 병원에서 뇌졸중 치료 경로를 개선하고 진단, 치료 및 결과를 향상시키는 것을 목표로 합니다.

SKU-66144